Richard A. Kayne - 31 Oct 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 31 Oct 2023
Net transaction value: +$72,815
SEC form: 4
Accepted by SEC: 02 Nov 2023, 21:21:30 UTC
Prior SEC filing: 30 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Richard A. Kayne

Key filing fact

Richard A. Kayne filed Form 4 for Eiger BioPharmaceuticals, Inc. on 02 Nov 2023.

Key facts

This page summarizes Richard A. Kayne's Form 4 filing for Eiger BioPharmaceuticals, Inc..
5 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Nov 2023, 21:21.

Change

Previous filing in this sequence was filed on 30 Oct 2023.
Current net transaction value: +$72,815.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EIGR transaction

Common Stock

Purchase

Transaction value: $3,147
Shares: +11,987
Change %: +0.24%
Price: $0.2625
Shares after: 5,108,973
Date: 31 Oct 2023
Ownership: See footnote.
Footnotes: F1, F3

EIGR transaction

Common Stock

Purchase

Transaction value: $3,228
Shares: +12,345
Change %: +0.24%
Price: $0.2615
Shares after: 5,121,318
Date: 31 Oct 2023
Ownership: See footnote.
Footnotes: F1, F3

EIGR transaction

Common Stock

Purchase

Transaction value: $31,505
Shares: +130,509
Change %: +2.5%
Price: $0.2414
Shares after: 5,251,827
Date: 31 Oct 2023
Ownership: See footnote.
Footnotes: F2, F3

EIGR transaction

Common Stock

Purchase

Transaction value: $27,970
Shares: +100,000
Change %: +1.9%
Price: $0.2797
Shares after: 5,351,827
Date: 01 Nov 2023
Ownership: See footnote.
Footnotes: F2, F3

EIGR transaction

Common Stock

Purchase

Transaction value: $6,966
Shares: +23,398
Change %: +0.44%
Price: $0.2977
Shares after: 5,375,225
Date: 02 Nov 2023
Ownership: See footnote.
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Mr. Kayne shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Mr. Kayne and Propel General Partner act as the general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.

Footnote F2

Mr. Kayne is the trustee and beneficiary of the Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999, a California trust (the "Family Trust"), and the Family Trust acquired the referenced shares of Common Stock.

Footnote F3

Mr. Kayne expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.